EICHORCondition: Breast Cancer · Sponsor: The Netherlands Cancer Institute
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This prospective, national, multi-centre study will include patients with stage III triple-negative breast cancer (TNBC) who are planned to start with standard (neo)adjuvant systemic treatment. The study will gather clinico-pathological, treatment and follow-up information of participating patients through Dutch databases. Participating patients will be asked to complete cancer specific and more generic quality of life questionnaires at nine time points during and after their anticancer treatment in a mobile application. For all patients who have consented to additional blood collection, to assess the course of dynamic ctDNA during (neo)adjuvant chemotherapy and its relation with outcome, two tubes will be collected at four different time points.
This description comes directly from the study's public registry record.
Pien Debets, Study coordinator · 0205129111 · p.debets@nki.nl
Ingrid Mandjes, Clinical Projects Manager
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Patients aged 18 years or older * Histologically confirmed adenocarcinoma of the breast * Assumed clinical or pathological stage III (TNM) breast cancer * Breast tumor must be: * HER2-negative: i.e. either score 0 or 1 at immunohistochemistry or score 2 at immunohistochemistry and negative at in situ hybridization (ISH, CISH or FISH) * Hormone receptor negative i.e. an estrogen receptor (ER) of \<10% and progesterone receptor (PR) of \<10%.; or in case of a histological grade III tumor an ER of \<50% and a PR of \<50%. * Patients are planned to receive the complete standard of care in the Netherlands; neo-adjuvant chemotherapy according to local practise * Participating patients have to be able to use a mobile phone, tablet, laptop and/or computer and understand the Dutch language Exclusion Criteria: * Evidence of distant metastases. Staging examinations should have been performed according to Dutch national guidelines. * Patients who are only treated systemically in the adjuvant setting * Participation in another clinical study with an treatment intervention during the course of this study.
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Medical spectrum Twente | Enschede, Overijssel, Netherlands | Recruiting |
| Amsterdam University Medical Center | Amsterdam, Netherlands | Not Yet Recruiting |
| The Netherlands Cancer Institute | Amsterdam, Netherlands | Recruiting |
| Amphia | Breda, Netherlands | Not Yet Recruiting |
| UMCG | Groningen, Netherlands | Recruiting |
| Maastricht University Medical Center | Maastricht, Netherlands | Recruiting |
| ErasmusMC | Rotterdam, Netherlands | Recruiting |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06931769